AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9704783 — intervention group
Group type: COMPARATOR
Intervention: Length of initial hospital stay < or = 24 hours
Number of subjects: 4323
Study 9704783 — intervention group
Group type: COMPARATOR
Intervention: Length of initial hospital stay 25 to 48 hours
Number of subjects: 4323
Study 9704783 — intervention group
Group type: COMPARATOR
Intervention: Maternal factors (preeclampsia, preterm delivery, instrument delivery)
Number of subjects: 4323
Study 9704783 — intervention group
Group type: COMPARATOR
Intervention: Length of initial hospital stay
Number of subjects: 4323
Study 8556789 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether (Art) 6 mg/kg followed by repeated dosing every 15 days for 3 times.
Number of subjects: 741
Study 8556789 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch) given at the same time as Art group.
Number of subjects: 741
Study 8556789 — intervention group
Group type: COMPARATOR
Intervention: Control group (Placebo)
Number of subjects: 741
Study 8556789 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether (Art)
Number of subjects: 741
Study 2399780 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (0.25 mg/kg in divided doses, followed by 0.50 mg/kg until blood pressure < 160/90 mmHg or total dose of 300 mg)
Number of subjects: 19
Study 2399780 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (infusion starting at 0.5 micrograms/kg/min, titrated up to 6.0 micrograms/kg/min)
Number of subjects: 19
Study 103378 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-food supplementation (Complan)
Number of subjects: 50
Study 103378 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 50
Study 31577104 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplement treatment
Number of subjects: 32
Study 28375803 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline as placebo (Group 1, n=193)
Number of subjects: 570
Study 28375803 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation cephalosporin (cefazolin; 1 g) (Group 2, n=191)
Number of subjects: 570
Study 28375803 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation cephalosporin (cefuroksim aksetil; 750 mg) (Group 3, n=186)
Number of subjects: 570
Study 24848637 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive exposure to e-cigarette cue
Number of subjects: 60
Study 24848637 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive exposure to combustible cigarette cue
Number of subjects: 60
Study 24848637 — intervention group
Group type: COMPARATOR
Intervention: Control cue (drinking bottled water)
Number of subjects: 60
Study 23623039 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 5059
Study 21221990 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise condition (REC) - 30 incline leg presses conducted during two sessions at 48 and 24 hours prior to IET.
Number of subjects: 6
Study 21221990 — intervention group
Group type: COMPARATOR
Intervention: Control condition (CC) - subjects refrained from strenuous exercise for 2 days prior to IET.
Number of subjects: 6
Study 21221990 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise condition (REC)
Number of subjects: 6
Study 21221990 — intervention group
Group type: COMPARATOR
Intervention: Control condition (CC)
Number of subjects: 6
Study 21221990 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise condition (REC) and Control condition (CC)
Number of subjects: 6
Study 19721138 — intervention group
Group type: EXPERIMENTAL
Intervention: Locked intramedullary nailing (IMN)
Number of subjects: 32
Study 19721138 — intervention group
Group type: COMPARATOR
Intervention: Dynamic compression plating (DCP)
Number of subjects: 32
Study 17199538 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen bioabsorbable membrane
Number of subjects: 25
Study 17199538 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix
Number of subjects: 25
Study 17199538 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone graft alone
Number of subjects: 25
Study 15741212 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg
Number of subjects: 600
Study 15741212 — intervention group
Group type: COMPARATOR
Intervention: Stavudine
Number of subjects: 600
Study 12120421 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets with a lower percentage of calories from fat
Number of subjects: 0
Study 12120421 — intervention group
Group type: COMPARATOR
Intervention: Diets with fat consumption within the range of 18-40% of energy
Number of subjects: 0
Study 12090591 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg of leuprorelin acetate depot for 8 weeks
Number of subjects: 34
Study 8947452 — intervention group
Group type: EXPERIMENTAL
Intervention: CarboMedics valve implantation (CM)
Number of subjects: 326
Study 8947452 — intervention group
Group type: COMPARATOR
Intervention: St. Jude Medical valve implantation (SJ)
Number of subjects: 326
Study 1932607 — intervention group
Group type: EXPERIMENTAL
Intervention: Ansaid (film‐coated 100 mg tablet)
Number of subjects: 23
Study 1932607 — intervention group
Group type: COMPARATOR
Intervention: Froben (sugar‐coated 100 mg tablet)
Number of subjects: 23
Study 1932607 — intervention group
Group type: EXPERIMENTAL
Intervention: S-configuration of flurbiprofen (Froben)
Number of subjects: 23
Study 1932607 — intervention group
Group type: COMPARATOR
Intervention: S-configuration of flurbiprofen (Ansaid)
Number of subjects: 23
Study 7242963 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium canrenoate
Number of subjects: 0
Study 7242963 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (in association with potassium canrenoate)
Number of subjects: 0
Study 31536994 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum bicarbonate levels
Number of subjects: 90
Study 31536994 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic acidosis prevalence
Number of subjects: 90
Study 31536994 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate levels
Number of subjects: 90
Study 31536994 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR levels
Number of subjects: 90
Study 28705885 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblast growth factor 23 quartile 4 (higher levels) in Study A
Number of subjects: 1002
Study 28705885 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblast growth factor 23 quartile 4 (higher levels) in Study B
Number of subjects: 1002
Study 28705885 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblast growth factor 23 quartile 4 in Study A
Number of subjects: 1002
Study 28705885 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblast growth factor 23 quartile 4 in Study B
Number of subjects: 1002
Study 28705885 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of fibroblast growth factor 23 to a model of annualized decline in eGFR≥3.0 ml/min per 1.73 m²
Number of subjects: 1002
Study 26562604 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/dl (low)
Number of subjects: 94
Study 26562604 — intervention group
Group type: EXPERIMENTAL
Intervention: 65 mg/dl (moderate)
Number of subjects: 94
Study 26562604 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/dl (placebo)
Number of subjects: 94
Study 23800483 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifamily psychoeducational psychotherapy (MF‐PEP)
Number of subjects: 165
Study 23800483 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 165
Study 21131295 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography and mammography (intervention group)
Number of subjects: 100000
Study 21131295 — intervention group
Group type: COMPARATOR
Intervention: Mammography only (control group)
Number of subjects: 100000
Study 19143752 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pimecrolimus cream 1% (n = 35)
Number of subjects: 70
Study 19143752 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone cream 0.1% (n = 35)
Number of subjects: 70
Study 17500625 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (details not specified)
Number of subjects: 174
Study 17500625 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy and affect at Year 2
Number of subjects: 174
Study 17500625 — intervention group
Group type: EXPERIMENTAL
Intervention: Original treatment condition
Number of subjects: 174
Study 17500625 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariance modeling analyses
Number of subjects: 174
Study 15024982 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaxigrip vaccine combined with Pneumo 23 and Avaxim vaccines
Number of subjects: 755
Study 15024982 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, but implied as those not receiving the combined vaccines)
Number of subjects: 755
Study 15024982 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaxigrip vaccine
Number of subjects: 755
Study 12033987 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 90 mg once daily
Number of subjects: 891
Study 12033987 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen 500 mg twice daily
Number of subjects: 891
Study 12033987 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 891
Study 9834800 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 0.15 mg.kg‐1 (MIV 15)
Number of subjects: 50
Study 9834800 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 0.25 mg.kg‐1 (MIV 25)
Number of subjects: 50
Study 9834800 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.3 mg.kg‐1 (ATR 30)
Number of subjects: 50
Study 9834800 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg.kg‐1 (ATR 50)
Number of subjects: 50
Study 9834800 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.06 mg.kg‐1 (VEC 06)
Number of subjects: 50
Study 9834800 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg.kg‐1 (VEC 10)
Number of subjects: 50
Study 8616117 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 and Cyclophosphamide 1200 mg/m2
Number of subjects: 105
Study 8616117 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 80 mg/m2 and Cyclophosphamide 900 mg/m2
Number of subjects: 105
Study 2748870 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (Apo) HCl 0.25, 0.5, 0.75, and 1.0 mg sc
Number of subjects: 28
Study 2748870 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (Apo) HCl
Number of subjects: 28
Study 2748870 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (open trial)
Number of subjects: 28
Study 2748870 — intervention group
Group type: COMPARATOR
Intervention: Apomorphine (Apo) HCl 3.5, 5.0, 7.0, and 10.5 ug/kg sc
Number of subjects: 28
Study 371030 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice a day
Number of subjects: 40
Study 371030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31808659 — intervention group
Group type: COMPARATOR
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 120
Study 31808659 — intervention group
Group type: COMPARATOR
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 120
Study 31426703 — intervention group
Group type: EXPERIMENTAL
Intervention: Interarytenoid injection augmentation
Number of subjects: 30
Study 31426703 — intervention group
Group type: COMPARATOR
Intervention: Preoperative Penetration‐Aspiration Scale scores
Number of subjects: 30
Study 31426703 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative Penetration‐Aspiration Scale scores
Number of subjects: 30
Study 28202370 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing & PRP injection/gel application (study group A)
Number of subjects: 72
Study 28202370 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed intramedullary nailing & PRP injection (subgroup A1)
Number of subjects: 72
Study 28202370 — intervention group
Group type: EXPERIMENTAL
Intervention: Open intramedullary nailing & PRP gel with fibrin membrane (subgroup A2)
Number of subjects: 72
Study 28202370 — intervention group
Group type: COMPARATOR
Intervention: Closed intramedullary nailing (subgroup B1)
Number of subjects: 72
Study 28202370 — intervention group
Group type: COMPARATOR
Intervention: Open intramedullary nailing (subgroup B2)
Number of subjects: 72
Study 26096484 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injections of corticosteroids with lidocaine
Number of subjects: 400
Study 26096484 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine only
Number of subjects: 400
Study 23286421 — intervention group
Group type: EXPERIMENTAL
Intervention: Kung Fu training for 6 months
Number of subjects: 0
Study 23286421 — intervention group
Group type: COMPARATOR
Intervention: Placebo-exercise intervention
Number of subjects: 0
Study 21970138 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB) with 0.2 ml/kg levobupivacaine
Number of subjects: 70
Study 21970138 — intervention group
Group type: COMPARATOR
Intervention: Caudal block (CB) with 1 ml/kg levobupivacaine
Number of subjects: 70
Study 21970138 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB)
Number of subjects: 70
Study 21970138 — intervention group
Group type: COMPARATOR
Intervention: Caudal block (CB)
Number of subjects: 70
Study 19280083 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 48
Study 19280083 — intervention group
Group type: COMPARATOR
Intervention: Vocational Service
Number of subjects: 48
Study 19280083 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS and Vocational Service
Number of subjects: 48
Study 16400054 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylalanine intake of 48 mg x kg(‐1) x d(‐1)
Number of subjects: 5
Study 16400054 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded intakes of phenylalanine (5, 10, 15, 25, 35, 45, 60, and 70 mg x kg(‐1) x d(‐1))
Number of subjects: 5
Study 15063762 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic polymorphisms in IL4, IL8RB, IL10RA, PRL, ADA, NFKB1, GRAP2, CABIN1, IFNAR2, IFI27, IFI41, TNFRSF1A, ALDOB, AP1B1, SULT2B1, EGF, EGFR, TGFB1, LTBP2, and CD4
Number of subjects: 238
Study 15063762 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic polymorphisms in IL1B, IL1RL1, IL2RB, IL12RB1, IL18R1, STAT5A, GRAP2, CABIN1, IFNAR1, Mx1, BMP8, FGL1, LTBP2, CD34, and CD80
Number of subjects: 238
Study 11284803 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg levocetirizine
Number of subjects: 24
Study 11284803 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cetirizine
Number of subjects: 24
Study 11284803 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg dextrocetirizine
Number of subjects: 24
Study 11284803 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 24
Study 9815721 — intervention group
Group type: EXPERIMENTAL
Intervention: LSF, 1.5 mg/kg i.v. bolus every 6 h during IL-2 therapy
Number of subjects: 53
Study 9815721 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 6 h during IL-2 therapy
Number of subjects: 53
Study 9815721 — intervention group
Group type: EXPERIMENTAL
Intervention: LSF
Number of subjects: 53
Study 9815721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 8484166 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilisation with the aircast splint (Group B)
Number of subjects: 120
Study 8484166 — intervention group
Group type: EXPERIMENTAL
Intervention: Unna's paste dressing for two weeks with subsequent tape dressings and immediate mobilisation (Group C)
Number of subjects: 120
Study 8484166 — intervention group
Group type: COMPARATOR
Intervention: Immobilisation in a plaster cast for three weeks followed by mobilisation with the aircast splint (Group A)
Number of subjects: 120
Study 3680816 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniphyl (once-a-day theophylline formulation) after breakfast
Number of subjects: 8
Study 3680816 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniphyl (once-a-day theophylline formulation) after overnight fast
Number of subjects: 8
Study 3680816 — intervention group
Group type: COMPARATOR
Intervention: Reference theophylline solution
Number of subjects: 8
Study 29961666 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention trial
Number of subjects: 0
Study 27478057 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care tools and care facilitation
Number of subjects: 0
Study 27478057 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based therapy tools and increased team meetings
Number of subjects: 0
Study 27478057 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for primary care providers
Number of subjects: 0
Study 25338241 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected collection technique
Number of subjects: 54
Study 25338241 — intervention group
Group type: COMPARATOR
Intervention: Traditional collection technique
Number of subjects: 54
Study 23454601 — intervention group
Group type: EXPERIMENTAL
Intervention: WebChoice intervention
Number of subjects: 325
Study 20032169 — intervention group
Group type: EXPERIMENTAL
Intervention: PACCTS intervention (telephone-based support)
Number of subjects: 9
Study 19050530 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intravenous dosing of cefazolin
Number of subjects: 24
Study 19050530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative dosing by irrigation of cefazolin
Number of subjects: 24
Study 16631656 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump, EC with closed SMA circuit and no pump suckers (n = 20)
Number of subjects: 80
Study 16631656 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump, EC with open SMA circuit and pump suckers (n = 20)
Number of subjects: 80
Study 16631656 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump (beating heart) and heparin 3 mg/kg (n = 20)
Number of subjects: 80
Study 16631656 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump (beating heart) and heparin 1 mg/kg (n = 20)
Number of subjects: 80
Study 16631656 — intervention group
Group type: COMPARATOR
Intervention: On-pump groups (1 and 2)
Number of subjects: 80
Study 16631656 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study 14557556 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA+
Number of subjects: 21
Study 14557556 — intervention group
Group type: EXPERIMENTAL
Intervention: GLX
Number of subjects: 21
Study 14557556 — intervention group
Group type: EXPERIMENTAL
Intervention: NAAt
Number of subjects: 21
Study 14557556 — intervention group
Group type: EXPERIMENTAL
Intervention: GLX/NAAt ratio
Number of subjects: 21
Study 14557556 — intervention group
Group type: EXPERIMENTAL
Intervention: GLX/Ins ratio
Number of subjects: 21
Study 14557556 — intervention group
Group type: EXPERIMENTAL
Intervention: Ins
Number of subjects: 21
Study 14557556 — intervention group
Group type: EXPERIMENTAL
Intervention: Cr
Number of subjects: 21
Study 14557556 — intervention group
Group type: EXPERIMENTAL
Intervention: Cho
Number of subjects: 21
Study 11865269 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (10 microg/kg/min, increased to 20 microg/kg/min if needed)
Number of subjects: 42
Study 11865269 — intervention group
Group type: COMPARATOR
Intervention: Dopamine (10 microg/kg/min, increased to 20 microg/kg/min if needed)
Number of subjects: 42
Study 11865269 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (at 24 hours)
Number of subjects: 42
Study 11865269 — intervention group
Group type: COMPARATOR
Intervention: Both dobutamine and dopamine
Number of subjects: 42
Study 11865269 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine and dopamine
Number of subjects: 42
Study 9696209 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IgG antibodies to C. trachomatis in poor responders (44.7%)
Number of subjects: 323
Study 9696209 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients undergoing IVF (36%)
Number of subjects: 323
Study 10150262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam (1.0 to 2.0 g ampicillin plus 0.5 to 1.0 g sulbactam every 6 hours)
Number of subjects: 76
Study 10150262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin (1.0 to 2.0 g every 6 hours)
Number of subjects: 76
Study 10150262 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin/sulbactam
Number of subjects: 76
Study 10150262 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 76
Study 10150262 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 76
Study 3190058 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (2 g/d for 2 weeks, and 1 g/d for 6 weeks)
Number of subjects: 10
Study 3190058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3190058 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 10
Study 31099167 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectator group watching professional baseball games at the ballpark for 2 months (median 6 days, interquartile range 4-10 days)
Number of subjects: 58
Study 31099167 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list group maintaining daily routines
Number of subjects: 58
Study 28710996 — intervention group
Group type: EXPERIMENTAL
Intervention: CE‐Marked Alere™ HIV Combo
Number of subjects: 5029
Study 28710996 — intervention group
Group type: EXPERIMENTAL
Intervention: Alere Determine™ HIV‐1/2 Ag/Ab Combo
Number of subjects: 5029
Study 28710996 — intervention group
Group type: EXPERIMENTAL
Intervention: GS HIV Combo Ag/Ab EIA
Number of subjects: 5029
Study 28710996 — intervention group
Group type: COMPARATOR
Intervention: Multispot®
Number of subjects: 5029
Study 28710996 — intervention group
Group type: COMPARATOR
Intervention: Western Blot (WB)
Number of subjects: 5029
Study 28710996 — intervention group
Group type: COMPARATOR
Intervention: Geenius™ (Bio‐Rad)
Number of subjects: 5029
Study 26582611 — intervention group
Group type: EXPERIMENTAL
Intervention: Head elevated (10° angle of inclination)
Number of subjects: 52
Study 26582611 — intervention group
Group type: COMPARATOR
Intervention: Head in neutral position (face parallel to the operating room table)
Number of subjects: 52
Study 23752604 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF therapy and CVC-related sepsis
Number of subjects: 59
Study 23752604 — intervention group
Group type: COMPARATOR
Intervention: Pre-treatment levels
Number of subjects: 59
Study 23752604 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 levels in sepsis
Number of subjects: 59